INDSWIFT LABORATORIES
|
INDSWIFT LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 71.24 | 8.06 | -0.36 | -0.53 | -3.59 |
| CEPS(Rs) | 80.35 | 17.80 | 21.81 | 14.24 | 11.66 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 157.64 | 84.25 | 68.33 | 66.35 | 70.21 |
| Tax Rate(%) | 27.56 | 44.72 | 117.15 | 117.48 | -7.17 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.71 | 18.90 | 18.66 | 20.35 | 18.32 |
| EBIT Margin(%) | 49.07 | 14.74 | 10.31 | 13.16 | 11.09 |
| Pre Tax Margin(%) | 45.11 | 7.14 | 1.20 | 2.01 | -2.52 |
| PAT Margin (%) | 32.68 | 3.94 | -0.21 | -0.35 | -2.71 |
| Cash Profit Margin (%) | 36.81 | 8.68 | 12.30 | 9.37 | 8.79 |
| Performance Ratios | |||||
| ROA(%) | 28.79 | 2.70 | -0.12 | -0.18 | -1.17 |
| ROE(%) | 58.97 | 10.61 | -0.54 | -0.78 | -5.56 |
| ROCE(%) | 55.13 | 13.25 | 7.88 | 8.31 | 5.97 |
| Asset Turnover(x) | 0.88 | 0.68 | 0.60 | 0.51 | 0.43 |
| Sales/Fixed Asset(x) | 1.93 | 0.92 | 0.80 | 0.67 | 0.57 |
| Working Capital/Sales(x) | 2.93 | 1.53 | 1.42 | 1.43 | 1.45 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.52 | 1.09 | 1.25 | 1.48 | 1.75 |
| Receivable days | 95.44 | 144.51 | 154.46 | 168.41 | 174.12 |
| Inventory Days | 63.55 | 130.51 | 140.01 | 145.99 | 153.65 |
| Payable days | 82.21 | 105.77 | 106.89 | 110.78 | 120.50 |
| Valuation Parameters | |||||
| PER(x) | 1.38 | 6.86 | - | - | - |
| PCE(x) | 1.22 | 3.10 | 3.04 | 5.06 | 1.86 |
| Price/Book(x) | 0.62 | 0.66 | 0.97 | 1.09 | 0.31 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.13 | 0.96 | 1.26 | 1.59 | 1.47 |
| EV/Core EBITDA(x) | 0.54 | 4.42 | 5.49 | 6.90 | 6.49 |
| EV/EBIT(x) | 0.26 | 6.49 | 12.15 | 12.00 | 13.22 |
| EV/CE(x) | 0.17 | 0.86 | 0.75 | 0.81 | 0.64 |
| M Cap / Sales | 0.45 | 0.27 | 0.38 | 0.48 | 0.16 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.10 | 16.23 | 16.54 | 14.33 | 3.05 |
| Core EBITDA Growth(%) | 14.04 | 9.86 | 16.35 | 16.15 | 8.54 |
| EBIT Growth(%) | 254.17 | 65.33 | -8.58 | 36.08 | -38.78 |
| PAT Growth(%) | 781.13 | 2,325.72 | 31.72 | 85.15 | -173.20 |
| EPS Growth(%) | 784.43 | 2,314.84 | 31.72 | 85.15 | -158.93 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | 1.71 | 2.33 | 2.56 | 2.48 |
| Current Ratio(x) | 2.99 | 3.13 | 3.21 | 2.99 | 2.67 |
| Quick Ratio(x) | 2.94 | 1.95 | 1.93 | 1.80 | 1.61 |
| Interest Cover(x) | 12.38 | 1.94 | 1.13 | 1.18 | 0.81 |
| Total Debt/Mcap(x) | 0.02 | 2.61 | 2.40 | 2.36 | 8.04 |
Compare Financial Ratios of peers of INDSWIFT LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDSWIFT LABORATORIES | ₹631.1 Cr | 0.7% | 9.1% | 19.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹441,838.0 Cr | 1% | 4.6% | 47.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,107.0 Cr | 1% | -3.2% | 59.3% | Stock Analytics | |
| CIPLA | ₹120,270.0 Cr | -1.1% | -0.3% | 20.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹113,077.0 Cr | 2.2% | 12.1% | 21.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,553.2 Cr | -2.7% | 0.8% | 43.8% | Stock Analytics | |
INDSWIFT LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDSWIFT LABORATORIES | 0.7% |
9.1% |
19.9% |
| SENSEX | -2.1% |
-2% |
11.3% |
You may also like the below Video Courses
